Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

The introduction of PDE5 inhibitors as safe and well-tolerated orally active drugs for the treatment of ... The application of PDE4 inhibitors appears to be a promising option to facilitate ...

The Phase 1 study will evaluate PALI-2108 in a single-center, double-blind, placebo-controlled study focused on safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, ...

Use of sodium glucose cotransporter 2 (SGLT-2) inhibitor drugs to treat type 2 diabetes may also help to lower the risk of ...

PALI-2108 is an orally administered, locally acting colon-specific PDE4 inhibitor prodrug in development for patients ... PALI-2108, and higher drug manufacturing costs, were offset by a decrease in ...

Targeted, better-tolerated oral PDE4 inhibitors are an unmet need in inflammatory bowel disease (IBD)PALI-2108 demonstrates in ex vivo studies; ...

Over the last few years, the SARS-CoV-2 virus, responsible for COVID-19, has undergone significant changes, evolving from the ...

What makes this biotech idea to look into, is that it is not just looking to develop another calcineurin inhibitor to help these patients. Matter of fact, this drug has been the standard of care ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development ... to provide API and manufacture drug product; our ability to enter into commercial ...

This orally administered, colon-specific phosphodiesterase-4 (PDE4) inhibitor prodrug is in development for patients ... our ability to identify and qualify manufacturers to provide API and ...